Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03768414 | Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers | completed | Phase 3 | 452 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 12, 2026 | clinicaltrials |
| NCT07320950 | Neuroprotective Effect of Neurotropin on Chronic OXA-induced Neurotoxicity in Stage II and Stage III CRC Patients | completed | Phase 3 | 333 | Sun Yat-sen UniversityOTHER | 1 | Jan 6, 2026 |
| NCT05215379 | Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer | completed | Phase 2 / Phase 3 | 201 | Changhai HospitalOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT02314182 | GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis(GRECCAR8) | completed | Phase 3 | 5 | Hospices Civils de LyonOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT03223376 | A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)(FRUTIGA) | completed | Phase 3 | 703 | Hutchison Medipharma LimitedINDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05600309 | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study | completed | Phase 3 | 94 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT02967289 | IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting(IROCAS) | completed | Phase 3 | 792 | UNICANCEROTHER | 2 | Nov 17, 2025 | clinicaltrials |
| NCT03269994 | Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy? | completed | Phase 3 | 967 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Oct 21, 2025 | clinicaltrials |
| NCT03412773 | A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) | completed | Phase 3 | 684 | BeiGeneINDUSTRY | 11 | Oct 14, 2025 | clinicaltrials |
| NCT02799212 | Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma(SOMAPROTECT01) | completed | Phase 3 | 179 | Hospices Civils de LyonOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT03062358 | Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394) | completed | Phase 3 | 453 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Sep 30, 2025 | clinicaltrials |
| NCT01999634 | Monitoring by Microdialysis of Postoperative Complications After Proctectomy(MTM-COLON-II) | completed | Phase 3 | 21 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT04487067 | A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista(AMETHISTA) | completed | Phase 3 | 152 | Hoffmann-La RocheINDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT01727388 | Informativeness to Digital Rectal Examination(RIFIONA) | completed | Phase 3 | 320 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT04534075 | Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial(FIDURA) | completed | Phase 3 | 354 | Sahlgrenska University HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT02605265 | Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1(CinClare) | completed | Phase 3 | 356 | Fudan UniversityOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT04941300 | ColoRectal Cancer Screening for Southern California Community Health Centers | completed | Phase 3 | 55,999 | University of California, San DiegoOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer(CheckMate649) | completed | Phase 3 | 2,031 | Bristol-Myers SquibbINDUSTRY | 29 | Aug 7, 2025 | clinicaltrials |
| NCT03434678 | Use of Epidurals Intraoperatively for Patients Undergoing Pancreas Resection | completed | Phase 3 | 133 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT03783442 | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 3 | 649 | BeiGeneINDUSTRY | 16 | Jul 29, 2025 | clinicaltrials |
| NCT01815853 | Neoadjuvant Chemoradiotherapy vs. Chemotherapy Followed by Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer(Neo-CRAG) | completed | Phase 3 | 620 | Sun Yat-sen UniversityOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT01804790 | Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer(Néofirinox) | completed | Phase 3 | 461 | UNICANCEROTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT04082364 | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer(MAHOGANY) | completed | Phase 2 / Phase 3 | 82 | MacroGenicsINDUSTRY | 9 | Jun 8, 2025 | clinicaltrials |
| NCT03206151 | CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer | completed | Phase 3 | 520 | Taizhou Mabtech Pharmaceutical Co.,LtdINDUSTRY | 1 | May 23, 2025 | clinicaltrials |
| NCT00806611 | Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer | completed | Phase 3 | 438 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT02764801 | Contrast-enhanced Ultrasound Evaluation of Chemoembolization | completed | Phase 3 | 131 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT04032119 | RCT of Gastric ESD With or Without Epineprhine Added Solution | completed | Phase 3 | 800 | Chinese University of Hong KongOTHER | 4 | May 4, 2025 | clinicaltrials |
| NCT00357682 | A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia(AspECT) | completed | Phase 3 | 2,557 | University of OxfordOTHER | 0 | May 1, 2025 | clinicaltrials |
| NCT05924880 | A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)(TopDouble) | completed | Phase 3 | 116 | AstraZenecaINDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT03468335 | 2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy(PREDICT) | completed | Phase 3 | 151 | AIO-Studien-gGmbHOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT02934529 | Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab(AIO-KRK-0114) | completed | Phase 3 | 673 | Ludwig-Maximilians - University of MunichOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT04229004 | A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer | completed | Phase 3 | 502 | Pancreatic Cancer Action NetworkOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04322539 | A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer(FRESCO-2) | completed | Phase 3 | 691 | Hutchison Medipharma LimitedINDUSTRY | 14 | Apr 4, 2025 | clinicaltrials |
| NCT01249352 | A Study of Chemoradiation Associated with Nimotuzumab As the Treatment of Locally Advanced Esophageal Cancer(NICE) | completed | Phase 2 / Phase 3 | 104 | Eurofarma Laboratorios S.A.INDUSTRY | 1 | Mar 31, 2025 | clinicaltrials |
| NCT02457156 | Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy(PANasta) | completed | Phase 3 | 295 | University of LiverpoolOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 3 | 743 | Bristol-Myers SquibbINDUSTRY | 22 | Feb 17, 2025 | clinicaltrials |
| NCT02349412 | Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers | completed | Phase 3 | 405 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT02162563 | Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases(CAIRO5) | completed | Phase 3 | 530 | Dutch Colorectal Cancer GroupOTHER | 2 | Feb 6, 2025 | clinicaltrials |
| NCT01878422 | Sequential Treatment Strategy for Metastatic Colorectal Cancer(ITACa) | completed | Phase 3 | 376 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT04499924 | Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer(MOUNTAINEER-02) | completed | Phase 2 / Phase 3 | 17 | Seagen Inc.INDUSTRY | 6 | Jan 22, 2025 | clinicaltrials |
| NCT06775652 | Neoadjuvant Chemoradiotherapy Plus Surgery vs. Surgery Plus Adjuvant Therapy for ESCC(ESCC) | completed | Phase 3 | 254 | Yongtao HanOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT03511963 | A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC | completed | Phase 3 | 677 | Shanghai Henlius BiotechINDUSTRY | 1 | Dec 31, 2024 | clinicaltrials |
| NCT04340193 | A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer(CheckMate 74W) | completed | Phase 3 | 26 | Bristol-Myers SquibbINDUSTRY | 19 | Nov 26, 2024 | clinicaltrials |
| NCT02578368 | Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction(FLOT5) | completed | Phase 3 | 183 | Krankenhaus NordwestOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT04456699 | Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) | completed | Phase 3 | 335 | Merck Sharp & Dohme LLCINDUSTRY | 18 | Oct 29, 2024 | clinicaltrials |
| NCT02494973 | Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases(PACHA-01) | completed | Phase 2 / Phase 3 | 104 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Oct 28, 2024 | clinicaltrials |
| NCT03430843 | A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 3 | 512 | BeiGeneINDUSTRY | 11 | Oct 26, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jan 12, 2026source: clinicaltrials